Phase 3 Trial Begins for Bispecific Antibody Aiming to Challenge Keytruda's Dominance

Bristol Myers Squibb (BMS) and BioNTech are jointly developing Pumitamig (BNT327), a next-generation bispecific antibody, and have initiated patient enrollment in a global Phase 3 trial (ROSETTA Lung-202, NCT07361510). This trial will evaluate Pumitamig in patients with previously untreated, advanced or metastatic non-small cell lung cancer (NSCLC) who have a PD-L1 expression level of 50% or higher. The primary objective is to demonstrate superiority compared to Keytruda (pembrolizumab), a standard-of-care, single-agent monoclonal antibody from Merck, in a head-to-head comparison. This trial directly targets the market leader in immune-oncology, garnering significant attention from the global biotech industry.

Technical Differentiation and Clinical Rationale of PD-L1 and VEGF-A Dual Blockade

Pumitamig is a bispecific antibody that simultaneously blocks PD-L1, an immune evasion mechanism of cancer cells, and vascular endothelial growth factor A (VEGF-A), which promotes angiogenesis within the tumor. By addressing the immunosuppressive environment within the tumor microenvironment and blocking nutrient supply to the tumor, Pumitamig is designed to achieve synergistic effects compared to single-agent therapies. In a previously reported Phase 2 trial, Pumitamig demonstrated a high objective response rate (ORR) of 92.3% in patients with NSCLC and a PD-L1 expression level of 50% or higher, indicating strong efficacy. This suggests that Pumitamig has the potential to overcome the limitations of existing immune checkpoint inhibitors and maximize survival benefits for patients.

Potential to Disrupt a $31.7 Billion Market

The global NSCLC treatment market is estimated at approximately $22 billion to $33 billion in 2025 and is projected to grow rapidly to over $70 billion by the mid-2030s. Keytruda, which has held a dominant position in this market, achieved global sales of $31.7 billion in 2025, setting an unprecedented record in cancer treatment. If Pumitamig demonstrates superior progression-free survival (PFS) or overall survival (OS) compared to Keytruda in this Phase 3 trial, it could lead to a paradigm shift in the first-line treatment of NSCLC. This would not only represent the success of a new drug but also fundamentally reshape the multi-billion dollar immune-oncology market.

Strategic Value Evidenced by a $11.1 Billion Mega-Deal

The partnership between the two companies was established through a $11.1 billion mega-deal in June 2025, which is considered one of the largest transactions in the recent biotech industry. Under the terms of the agreement, BMS will provide BioNTech with an upfront payment of $1.5 billion and guaranteed annual payments of $2 billion through 2028, with additional milestone payments of up to $7.6 billion based on development and regulatory achievements. The two companies have agreed to equally share global development costs and future commercial profits on a 50/50 basis, establishing a close collaborative partnership. This significant investment reflects BMS's strong confidence in the clinical success and market potential of Pumitamig.

Market Perspective on Regulatory Hurdles and Future Timelines

The Phase 3 trial is scheduled to begin in March 2026, with patient enrollment marking the start of the data collection phase. The success of this trial will be a critical milestone for regulatory approval by the Food and Drug Administration (FDA) and will determine the commercial success of Pumitamig. However, the management of potential adverse effects associated with VEGF inhibition, such as hypertension and bleeding, and the 3-grade or higher adverse event rate of 54.7% reported in Phase 2, will be key factors in obtaining regulatory approval. Investors should closely monitor the interim analysis and safety profile data to assess whether Pumitamig can surpass existing standard treatments and emerge as an innovative new drug.